共 217 条
[1]
Hu JR(2019)Cardiovascular toxicities associated with immune checkpoint inhibitors Cardiovasc Res 115 854-868
[2]
Florido R(2018)Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study Lancet Oncol 12 1579-1589
[3]
Lipson EJ(2006)Diagnosis of myocarditis: death of Dallas criteria Circulation 113 593-595
[4]
Naidoo J(2013)Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases Eur Heart J 140 80-91
[5]
Ardehali R(2019)Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology Circulation 18 230-241
[6]
Tocchetti CG(2020)NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020 J Natl Compr Canc Netw 136 2085-2087
[7]
Lyon AR(2017)Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity Circulation 3 e59125-1487
[8]
Padera RF(2018)Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight 53 1475-921
[9]
Johnson DB(2009)Cardiovascular magnetic resonance in myocarditis: a JACC white paper J Am Coll Cardiol 16 11795468211065782-undefined
[10]
Moslehi J(2002)Takotsubo syndrome: a review of presentation, diagnosis and management Clin Med Insights Cardiol 76 914-undefined